Expression and cellular immunogenicity of a transgenic antigen driven by endogenous poxviral early promoters at their authentic loci in MVA.
CD8(+) T cell responses to vaccinia virus are directed almost exclusively against early gene products. The attenuated strain modified vaccinia virus Ankara (MVA) is under evaluation in clinical trials of new vaccines designed to elicit cellular immune responses against pathogens including Plasmodium...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2012-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3384612?pdf=render |
id |
doaj-637a937165534b80ab7489b613ec72bf |
---|---|
record_format |
Article |
spelling |
doaj-637a937165534b80ab7489b613ec72bf2020-11-25T00:51:39ZengPublic Library of Science (PLoS)PLoS ONE1932-62032012-01-0176e4016710.1371/journal.pone.0040167Expression and cellular immunogenicity of a transgenic antigen driven by endogenous poxviral early promoters at their authentic loci in MVA.Toritse OrubuNaif Khalaf AlharbiTeresa LambeSarah C GilbertMatthew G CottinghamCD8(+) T cell responses to vaccinia virus are directed almost exclusively against early gene products. The attenuated strain modified vaccinia virus Ankara (MVA) is under evaluation in clinical trials of new vaccines designed to elicit cellular immune responses against pathogens including Plasmodium spp., M. tuberculosis and HIV-1. All of these recombinant MVAs (rMVA) utilize the well-established method of linking the gene of interest to a cloned poxviral promoter prior to insertion into the viral genome at a suitable locus by homologous recombination in infected cells. Using BAC recombineering, we show that potent early promoters that drive expression of non-functional or non-essential MVA open reading frames (ORFs) can be harnessed for immunogenic expression of recombinant antigen. Precise replacement of the MVA orthologs of C11R, F11L, A44L and B8R with a model antigen positioned to use the same translation initiation codon allowed early transgene expression similar to or slightly greater than that achieved by the commonly-used p7.5 or short synthetic promoters. The frequency of antigen-specific CD8(+) T cells induced in mice by single shot or adenovirus-prime, rMVA-boost vaccination were similarly equal or marginally enhanced using endogenous promoters at their authentic genomic loci compared to the traditional constructs. The enhancement in immunogenicity observed using the C11R or F11L promoters compared with p7.5 was similar to that obtained with the mH5 promoter compared with p7.5. Furthermore, the growth rates of the viruses were unimpaired and the insertions were genetically stable. Insertion of a transgenic ORF in place of a viral ORF by BAC recombineering can thus provide not only a potent promoter, but also, concomitantly, a suitable insertion site, potentially facilitating development of MVA vaccines expressing multiple recombinant antigens.http://europepmc.org/articles/PMC3384612?pdf=render |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Toritse Orubu Naif Khalaf Alharbi Teresa Lambe Sarah C Gilbert Matthew G Cottingham |
spellingShingle |
Toritse Orubu Naif Khalaf Alharbi Teresa Lambe Sarah C Gilbert Matthew G Cottingham Expression and cellular immunogenicity of a transgenic antigen driven by endogenous poxviral early promoters at their authentic loci in MVA. PLoS ONE |
author_facet |
Toritse Orubu Naif Khalaf Alharbi Teresa Lambe Sarah C Gilbert Matthew G Cottingham |
author_sort |
Toritse Orubu |
title |
Expression and cellular immunogenicity of a transgenic antigen driven by endogenous poxviral early promoters at their authentic loci in MVA. |
title_short |
Expression and cellular immunogenicity of a transgenic antigen driven by endogenous poxviral early promoters at their authentic loci in MVA. |
title_full |
Expression and cellular immunogenicity of a transgenic antigen driven by endogenous poxviral early promoters at their authentic loci in MVA. |
title_fullStr |
Expression and cellular immunogenicity of a transgenic antigen driven by endogenous poxviral early promoters at their authentic loci in MVA. |
title_full_unstemmed |
Expression and cellular immunogenicity of a transgenic antigen driven by endogenous poxviral early promoters at their authentic loci in MVA. |
title_sort |
expression and cellular immunogenicity of a transgenic antigen driven by endogenous poxviral early promoters at their authentic loci in mva. |
publisher |
Public Library of Science (PLoS) |
series |
PLoS ONE |
issn |
1932-6203 |
publishDate |
2012-01-01 |
description |
CD8(+) T cell responses to vaccinia virus are directed almost exclusively against early gene products. The attenuated strain modified vaccinia virus Ankara (MVA) is under evaluation in clinical trials of new vaccines designed to elicit cellular immune responses against pathogens including Plasmodium spp., M. tuberculosis and HIV-1. All of these recombinant MVAs (rMVA) utilize the well-established method of linking the gene of interest to a cloned poxviral promoter prior to insertion into the viral genome at a suitable locus by homologous recombination in infected cells. Using BAC recombineering, we show that potent early promoters that drive expression of non-functional or non-essential MVA open reading frames (ORFs) can be harnessed for immunogenic expression of recombinant antigen. Precise replacement of the MVA orthologs of C11R, F11L, A44L and B8R with a model antigen positioned to use the same translation initiation codon allowed early transgene expression similar to or slightly greater than that achieved by the commonly-used p7.5 or short synthetic promoters. The frequency of antigen-specific CD8(+) T cells induced in mice by single shot or adenovirus-prime, rMVA-boost vaccination were similarly equal or marginally enhanced using endogenous promoters at their authentic genomic loci compared to the traditional constructs. The enhancement in immunogenicity observed using the C11R or F11L promoters compared with p7.5 was similar to that obtained with the mH5 promoter compared with p7.5. Furthermore, the growth rates of the viruses were unimpaired and the insertions were genetically stable. Insertion of a transgenic ORF in place of a viral ORF by BAC recombineering can thus provide not only a potent promoter, but also, concomitantly, a suitable insertion site, potentially facilitating development of MVA vaccines expressing multiple recombinant antigens. |
url |
http://europepmc.org/articles/PMC3384612?pdf=render |
work_keys_str_mv |
AT toritseorubu expressionandcellularimmunogenicityofatransgenicantigendrivenbyendogenouspoxviralearlypromotersattheirauthenticlociinmva AT naifkhalafalharbi expressionandcellularimmunogenicityofatransgenicantigendrivenbyendogenouspoxviralearlypromotersattheirauthenticlociinmva AT teresalambe expressionandcellularimmunogenicityofatransgenicantigendrivenbyendogenouspoxviralearlypromotersattheirauthenticlociinmva AT sarahcgilbert expressionandcellularimmunogenicityofatransgenicantigendrivenbyendogenouspoxviralearlypromotersattheirauthenticlociinmva AT matthewgcottingham expressionandcellularimmunogenicityofatransgenicantigendrivenbyendogenouspoxviralearlypromotersattheirauthenticlociinmva |
_version_ |
1725244636961701888 |